Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival
In the last years we have witnessed tremendous advancements in the treatment landscape of metastatic breast cancer (MBC), leading to a progressive prolongation of progression-free survival and, in some cases, also of overall survival. This led to a substantial increase of advanced disease treatabili...
Gespeichert in:
| Veröffentlicht in: | ESMO open 2022-04, Vol.7 (2), p.100409-100409, Article 100409 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 100409 |
|---|---|
| container_issue | 2 |
| container_start_page | 100409 |
| container_title | ESMO open |
| container_volume | 7 |
| creator | Miglietta, F. Bottosso, M. Griguolo, G. Dieci, M.V. Guarneri, V. |
| description | In the last years we have witnessed tremendous advancements in the treatment landscape of metastatic breast cancer (MBC), leading to a progressive prolongation of progression-free survival and, in some cases, also of overall survival. This led to a substantial increase of advanced disease treatability. In the present review we comprehensively and critically describe the most significant progresses in the therapeutic scenario of MBC according to BC subtype. In particular, we reviewed studies reporting practice-changing data in hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative, HER2-positive and triple-negative BC, with also a hint to BRCA-related tumors and the emerging HER2-low-positive category.
•The treatment landscape of MBC has progressively widened in the last years.•Several therapeutic strategies proved to be capable of prolonging survival of patients with MBC.•We comprehensively reviewed practice-changing data on MBC treatment according to BC subtype. |
| doi_str_mv | 10.1016/j.esmoop.2022.100409 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8886005</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2059702922000308</els_id><sourcerecordid>2634846453</sourcerecordid><originalsourceid>FETCH-LOGICAL-c463t-c218f9a6b7accb504d7bedda63c6a14f1635cdada091a428e6107b1193c1881e3</originalsourceid><addsrcrecordid>eNp9UcFu1DAQtRCIVm3_oEI-ctnFdhwn4YCEKmiRinqhZ2tiz24dJXawvQH-HkdbSrlwsWfmzXsz9iPkkrMtZ1y9G7aYphDmrWBClBKTrHtBTgWru03DRPfyWXxCLlIaGGO8kaWoXpOTqhai6VR9SoavMIRIwS7gDU7oc6LO0wkzpAzZGdpHLCE1Kx5pLlle297THw_oKf6cwVvn9zTM2QWfChXKOccwBr9fgXSIi1tgPCevdjAmvHi8z8j950_frm42t3fXX64-3m6MVFXeGMHbXQeqb8CYvmbSNj1aC6oyCrjccVXVxoIF1nGQokXFWdNz3lWGty3H6ox8OOrOh35Ca8qyEUY9RzdB_KUDOP0v4t2D3odFt22rGKuLwNtHgRi-HzBlPblkcBzBYzgkLVQlW6lkXZVWeWw1MaQUcfc0hjO9OqUHfXRKr07po1OF9ub5ik-kP778fQOWj1ocRp2Mw-KAdRFN1ja4_0_4DZ-jqmc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2634846453</pqid></control><display><type>article</type><title>Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Miglietta, F. ; Bottosso, M. ; Griguolo, G. ; Dieci, M.V. ; Guarneri, V.</creator><creatorcontrib>Miglietta, F. ; Bottosso, M. ; Griguolo, G. ; Dieci, M.V. ; Guarneri, V.</creatorcontrib><description>In the last years we have witnessed tremendous advancements in the treatment landscape of metastatic breast cancer (MBC), leading to a progressive prolongation of progression-free survival and, in some cases, also of overall survival. This led to a substantial increase of advanced disease treatability. In the present review we comprehensively and critically describe the most significant progresses in the therapeutic scenario of MBC according to BC subtype. In particular, we reviewed studies reporting practice-changing data in hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative, HER2-positive and triple-negative BC, with also a hint to BRCA-related tumors and the emerging HER2-low-positive category.
•The treatment landscape of MBC has progressively widened in the last years.•Several therapeutic strategies proved to be capable of prolonging survival of patients with MBC.•We comprehensively reviewed practice-changing data on MBC treatment according to BC subtype.</description><identifier>ISSN: 2059-7029</identifier><identifier>EISSN: 2059-7029</identifier><identifier>DOI: 10.1016/j.esmoop.2022.100409</identifier><identifier>PMID: 35227965</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Breast Neoplasms - drug therapy ; chemotherapy ; endocrine therapy ; Female ; Humans ; metastatic breast cancer ; patient selection ; Progression-Free Survival ; Review ; targeted therapy</subject><ispartof>ESMO open, 2022-04, Vol.7 (2), p.100409-100409, Article 100409</ispartof><rights>2022 The Authors</rights><rights>Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.</rights><rights>2022 The Authors 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c463t-c218f9a6b7accb504d7bedda63c6a14f1635cdada091a428e6107b1193c1881e3</citedby><cites>FETCH-LOGICAL-c463t-c218f9a6b7accb504d7bedda63c6a14f1635cdada091a428e6107b1193c1881e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8886005/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8886005/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35227965$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Miglietta, F.</creatorcontrib><creatorcontrib>Bottosso, M.</creatorcontrib><creatorcontrib>Griguolo, G.</creatorcontrib><creatorcontrib>Dieci, M.V.</creatorcontrib><creatorcontrib>Guarneri, V.</creatorcontrib><title>Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival</title><title>ESMO open</title><addtitle>ESMO Open</addtitle><description>In the last years we have witnessed tremendous advancements in the treatment landscape of metastatic breast cancer (MBC), leading to a progressive prolongation of progression-free survival and, in some cases, also of overall survival. This led to a substantial increase of advanced disease treatability. In the present review we comprehensively and critically describe the most significant progresses in the therapeutic scenario of MBC according to BC subtype. In particular, we reviewed studies reporting practice-changing data in hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative, HER2-positive and triple-negative BC, with also a hint to BRCA-related tumors and the emerging HER2-low-positive category.
•The treatment landscape of MBC has progressively widened in the last years.•Several therapeutic strategies proved to be capable of prolonging survival of patients with MBC.•We comprehensively reviewed practice-changing data on MBC treatment according to BC subtype.</description><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Breast Neoplasms - drug therapy</subject><subject>chemotherapy</subject><subject>endocrine therapy</subject><subject>Female</subject><subject>Humans</subject><subject>metastatic breast cancer</subject><subject>patient selection</subject><subject>Progression-Free Survival</subject><subject>Review</subject><subject>targeted therapy</subject><issn>2059-7029</issn><issn>2059-7029</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UcFu1DAQtRCIVm3_oEI-ctnFdhwn4YCEKmiRinqhZ2tiz24dJXawvQH-HkdbSrlwsWfmzXsz9iPkkrMtZ1y9G7aYphDmrWBClBKTrHtBTgWru03DRPfyWXxCLlIaGGO8kaWoXpOTqhai6VR9SoavMIRIwS7gDU7oc6LO0wkzpAzZGdpHLCE1Kx5pLlle297THw_oKf6cwVvn9zTM2QWfChXKOccwBr9fgXSIi1tgPCevdjAmvHi8z8j950_frm42t3fXX64-3m6MVFXeGMHbXQeqb8CYvmbSNj1aC6oyCrjccVXVxoIF1nGQokXFWdNz3lWGty3H6ox8OOrOh35Ca8qyEUY9RzdB_KUDOP0v4t2D3odFt22rGKuLwNtHgRi-HzBlPblkcBzBYzgkLVQlW6lkXZVWeWw1MaQUcfc0hjO9OqUHfXRKr07po1OF9ub5ik-kP778fQOWj1ocRp2Mw-KAdRFN1ja4_0_4DZ-jqmc</recordid><startdate>20220401</startdate><enddate>20220401</enddate><creator>Miglietta, F.</creator><creator>Bottosso, M.</creator><creator>Griguolo, G.</creator><creator>Dieci, M.V.</creator><creator>Guarneri, V.</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20220401</creationdate><title>Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival</title><author>Miglietta, F. ; Bottosso, M. ; Griguolo, G. ; Dieci, M.V. ; Guarneri, V.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c463t-c218f9a6b7accb504d7bedda63c6a14f1635cdada091a428e6107b1193c1881e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Breast Neoplasms - drug therapy</topic><topic>chemotherapy</topic><topic>endocrine therapy</topic><topic>Female</topic><topic>Humans</topic><topic>metastatic breast cancer</topic><topic>patient selection</topic><topic>Progression-Free Survival</topic><topic>Review</topic><topic>targeted therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Miglietta, F.</creatorcontrib><creatorcontrib>Bottosso, M.</creatorcontrib><creatorcontrib>Griguolo, G.</creatorcontrib><creatorcontrib>Dieci, M.V.</creatorcontrib><creatorcontrib>Guarneri, V.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>ESMO open</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Miglietta, F.</au><au>Bottosso, M.</au><au>Griguolo, G.</au><au>Dieci, M.V.</au><au>Guarneri, V.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival</atitle><jtitle>ESMO open</jtitle><addtitle>ESMO Open</addtitle><date>2022-04-01</date><risdate>2022</risdate><volume>7</volume><issue>2</issue><spage>100409</spage><epage>100409</epage><pages>100409-100409</pages><artnum>100409</artnum><issn>2059-7029</issn><eissn>2059-7029</eissn><abstract>In the last years we have witnessed tremendous advancements in the treatment landscape of metastatic breast cancer (MBC), leading to a progressive prolongation of progression-free survival and, in some cases, also of overall survival. This led to a substantial increase of advanced disease treatability. In the present review we comprehensively and critically describe the most significant progresses in the therapeutic scenario of MBC according to BC subtype. In particular, we reviewed studies reporting practice-changing data in hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative, HER2-positive and triple-negative BC, with also a hint to BRCA-related tumors and the emerging HER2-low-positive category.
•The treatment landscape of MBC has progressively widened in the last years.•Several therapeutic strategies proved to be capable of prolonging survival of patients with MBC.•We comprehensively reviewed practice-changing data on MBC treatment according to BC subtype.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>35227965</pmid><doi>10.1016/j.esmoop.2022.100409</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2059-7029 |
| ispartof | ESMO open, 2022-04, Vol.7 (2), p.100409-100409, Article 100409 |
| issn | 2059-7029 2059-7029 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8886005 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use Breast Neoplasms - drug therapy chemotherapy endocrine therapy Female Humans metastatic breast cancer patient selection Progression-Free Survival Review targeted therapy |
| title | Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T19%3A54%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Major%20advancements%20in%20metastatic%20breast%20cancer%20treatment:%20when%20expanding%20options%20means%20prolonging%20survival&rft.jtitle=ESMO%20open&rft.au=Miglietta,%20F.&rft.date=2022-04-01&rft.volume=7&rft.issue=2&rft.spage=100409&rft.epage=100409&rft.pages=100409-100409&rft.artnum=100409&rft.issn=2059-7029&rft.eissn=2059-7029&rft_id=info:doi/10.1016/j.esmoop.2022.100409&rft_dat=%3Cproquest_pubme%3E2634846453%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2634846453&rft_id=info:pmid/35227965&rft_els_id=S2059702922000308&rfr_iscdi=true |